YPSOMED HLDG N
YPSOMED HLDG N operates in Diversified Metals & Mining.
YPSOMED HLDG N (OWX) - Net Assets
Latest net assets as of March 2024: €617.73 Million EUR
Based on the latest financial reports, YPSOMED HLDG N (OWX) has net assets worth €617.73 Million EUR as of March 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.10 Billion) and total liabilities (€483.66 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €617.73 Million |
| % of Total Assets | 56.09% |
| Annual Growth Rate | 10.77% |
| 5-Year Change | 64.65% |
| 10-Year Change | N/A |
| Growth Volatility | 13.92 |
YPSOMED HLDG N - Net Assets Trend (2017–2024)
This chart illustrates how YPSOMED HLDG N's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for YPSOMED HLDG N (2017–2024)
The table below shows the annual net assets of YPSOMED HLDG N from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-03-31 | €617.73 Million | +9.85% |
| 2023-03-31 | €562.33 Million | +43.25% |
| 2022-03-31 | €392.54 Million | -0.72% |
| 2021-03-31 | €395.38 Million | +5.39% |
| 2020-03-31 | €375.17 Million | -0.96% |
| 2019-03-31 | €378.80 Million | +10.91% |
| 2018-03-31 | €341.54 Million | +13.17% |
| 2017-03-31 | €301.80 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to YPSOMED HLDG N's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 85.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €572.08 Million | 92.61% |
| Other Components | €45.65 Million | 7.39% |
| Total Equity | €617.73 Million | 100.00% |
YPSOMED HLDG N Competitors by Market Cap
The table below lists competitors of YPSOMED HLDG N ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Oncozenge AB
ST:ONCOZ
|
$2.88 Million |
|
Spacetalk Ltd
AU:SPA
|
$2.88 Million |
|
Marquee Resources Ltd
AU:MQR
|
$2.88 Million |
|
Singularity Future Technology Ltd
NASDAQ:SGLY
|
$2.88 Million |
|
Rothwell International Co. Limited
KQ:900260
|
$2.88 Million |
|
Cytophage Technologies Ltd.
V:CYTO
|
$2.88 Million |
|
NOST.TERRA OIL+G. LS-001
F:LMU1
|
$2.88 Million |
|
Raj Rayon Industries Limited
NSE:RAJRILTD
|
$2.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in YPSOMED HLDG N's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 562,331,000 to 617,734,000, a change of 55,403,000 (9.9%).
- Net income of 78,366,000 contributed positively to equity growth.
- Dividend payments of 17,745,000 reduced retained earnings.
- Share repurchases of 1,325,000 reduced equity.
- New share issuances of 1,135,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €78.37 Million | +12.69% |
| Dividends Paid | €17.75 Million | -2.87% |
| Share Repurchases | €1.32 Million | -0.21% |
| Share Issuances | €1.14 Million | +0.18% |
| Other Changes | €-5.03 Million | -0.81% |
| Total Change | €- | 9.85% |
Book Value vs Market Value Analysis
This analysis compares YPSOMED HLDG N's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.75x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 12.77x to 6.75x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | €23.91 | €305.50 | x |
| 2018-03-31 | €27.10 | €305.50 | x |
| 2019-03-31 | €30.06 | €305.50 | x |
| 2020-03-31 | €29.77 | €305.50 | x |
| 2021-03-31 | €31.18 | €305.50 | x |
| 2022-03-31 | €30.94 | €305.50 | x |
| 2023-03-31 | €41.20 | €305.50 | x |
| 2024-03-31 | €45.26 | €305.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently YPSOMED HLDG N utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.69%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.29%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 1.78x
- Recent ROE (12.69%) is above the historical average (9.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 15.32% | 11.87% | 0.92x | 1.40x | €16.07 Million |
| 2018 | 15.24% | 11.17% | 0.93x | 1.46x | €17.91 Million |
| 2019 | 15.88% | 13.25% | 0.77x | 1.55x | €22.26 Million |
| 2020 | 3.05% | 2.91% | 0.58x | 1.80x | €-26.07 Million |
| 2021 | 1.47% | 1.44% | 0.56x | 1.82x | €-33.73 Million |
| 2022 | 5.89% | 4.97% | 0.61x | 1.93x | €-16.15 Million |
| 2023 | 9.12% | 10.31% | 0.58x | 1.53x | €-4.96 Million |
| 2024 | 12.69% | 14.29% | 0.50x | 1.78x | €16.59 Million |
Industry Comparison
This section compares YPSOMED HLDG N's net assets metrics with peer companies in the Other industry.
Industry Context
- Industry: Other
- Average net assets among peers: $114,212,818,724
- Average return on equity (ROE) among peers: -9.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| YPSOMED HLDG N (OWX) | €617.73 Million | 15.32% | 0.78x | $2.88 Million |
| HORIBA (01H) | $204.49 Billion | 10.42% | 0.82x | $989.01K |
| Tokyu Corporation (01T) | $779.37 Billion | 3.34% | 2.35x | $99.73K |
| GUANGZHOU AUTO -H- (02G) | $122.28 Billion | 6.59% | 0.55x | $4.05K |
| MOSAIC (02M) | $10.60 Billion | 4.43% | 0.90x | $280.83K |
| MOSAIC (02M.SG) (02M) | $9.56 Billion | 10.46% | 0.82x | $247.21K |
| CHINA JO-JO DRGSTRS (04CN.SG) (04CN) | $16.67 Million | -126.83% | 4.46x | $1.55 Million |
| KRAKATAU STEEL -B- (07K) | $552.59 Million | 3.52% | 4.72x | $166.99 |
| CN MODERN DAIRY (07M) | $7.12 Billion | -10.42% | 1.50x | $1.68K |
| TOURMALINE OIL (08T) | $7.22 Billion | 4.81% | 0.41x | $381.02K |
| ASIA CASSAVA RESOUR (0ACS) | $913.15 Million | 2.86% | 1.55x | $325.03 |